How much do oral PCSK9 inhibitors actually lower cholesterol?
Oral PCSK9 inhibitors are not a minor tweak—they deliver LDL cholesterol reductions that rival the injectable versions. In a phase 2 trial of MK-0616 (now called enlicitide), doses of 12 to 30 mg once daily lowered LDL cholesterol by 55.7% to 60.9% from baseline at 8 weeks, compared with placebo [2]. A phase 3 trial of enlicitide in patients with familial hypercholesterolemia (a genetic condition causing very high cholesterol) found a 58.2% reduction at 24 weeks [4]. Another oral drug, AZD0780, lowered LDL cholesterol by up to 50.7% in a phase 2 trial when added to statins [1]. Across five trials, a meta-analysis found an average LDL reduction of about 50% compared with placebo [3]. For context, that's roughly double what a typical statin achieves alone, and it's in the same ballpark as the injectable PCSK9 inhibitors [8].
How do they stack up against current non-statin options?
For people who need more than a statin, the current oral choices are ezetimibe and bempedoic acid—but oral PCSK9 inhibitors appear to be far more potent. In a head-to-head phase 3 trial, enlicitide lowered LDL cholesterol by 64.6% after 56 days, while ezetimibe lowered it by 27.8%, bempedoic acid by 6.3%, and the combination of both by 36.5% [6]. That's a dramatic difference: the oral PCSK9 inhibitor was superior to every comparator, meaning it could become the most effective non-statin pill available. Even when added to a statin, AZD0780 produced an additional ~50% reduction, with modeling suggesting a combination of rosuvastatin and AZD0780 could lower LDL by about 76% from baseline [9].
What's the catch? Safety and long-term data
The main caveat is that we don't yet know if these pills reduce heart attacks and strokes—the ultimate goal of cholesterol treatment. The trials so far have measured cholesterol levels, not cardiovascular events, and they've lasted only 8 to 52 weeks [2][4][5]. A meta-analysis of five trials found no increase in adverse events compared with placebo, which is reassuring, but it also noted that longer-term outcome trials are needed [3][7]. The good news is that the safety profile looks clean: in the largest trial to date (nearly 3,000 patients), adverse events were similar between enlicitide and placebo [5]. So the 'catch' is not safety—it's the lack of proof yet that these pills prevent heart disease. If ongoing outcome trials are positive, oral PCSK9 inhibitors could become a game-changer for the many patients who avoid injections [10].
About These Sources
This answer is built on 10 peer-reviewed studies — published from 2023 to 2026, 9 from 2024 or later, 4 in Q1 journals, collectively cited 259 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 40 papers retrieved from a database of over 500 million.
Sources used in this answer
An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia
In a phase 2 randomized trial (PURSUIT), the oral PCSK9 inhibitor AZD0780 lowered LDL cholesterol by 35.3% to 50.7% (placebo-corrected) at 12 weeks in patients on statins, with a safety profile similar to placebo.
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
In a phase 2b randomized trial, MK-0616 (oral PCSK9 inhibitor) lowered LDL cholesterol by 41.2% to 60.9% at 8 weeks across doses, with adverse events similar to placebo.
Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials.
A meta-analysis of five randomized trials (n=4226) found oral PCSK9 inhibitors reduced LDL cholesterol by a mean of 49.92% versus placebo, with similar safety, but called for longer-term cardiovascular outcome trials.
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
In a phase 3 randomized trial in patients with heterozygous familial hypercholesterolemia, enlicitide lowered LDL cholesterol by 58.2% at 24 weeks (placebo-adjusted difference -59.4%), with similar adverse events to placebo.
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.
In a large phase 3 randomized trial (n=2909), enlicitide lowered LDL cholesterol by 57.1% at 24 weeks versus 3.0% with placebo, with no apparent difference in adverse events.
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial.
In a phase 3 active-comparator trial, enlicitide lowered LDL cholesterol by 64.6% at day 56, significantly more than ezetimibe (27.8%), bempedoic acid (6.3%), or the combination (36.5%), with similar safety.
Meta-Analysis of Oral PCSK9 Inhibitors for Hypercholesterolemia in Adults: A Systematic Review and GRADE Assessment.
A meta-analysis of five trials (n=4232) found oral PCSK9 inhibitors reduced LDL cholesterol by a mean of 52.42 percentage points and ApoB by 43.03 points, with no significant differences in adverse events versus placebo.
Comparative Effectiveness of Statins Vs PCSK9 Inhibitors in High-Risk CV patients
A cross-sectional study of 180 high-risk patients found PCSK9 inhibitors (likely injectable) reduced LDL cholesterol by 58.2% versus 36.6% with statins, and fewer cardiovascular events (6.6% vs 15.5%).
Abstract 4359604: Model-Based Evaluation of LDL-C Lowering for Laroprovstat (AZD0780), An Oral Small Molecule PCSK9 Inhibitor, and Rosuvastatin
Modeling based on phase 2 data predicted that adding AZD0780 30 mg to rosuvastatin 20 mg would lower LDL cholesterol by about 76% at 12 weeks, supporting a co-formulation.
Oral PCSK9 Inhibitors: Will They Work?
A review of oral PCSK9 inhibitors notes that enlicitide lowers LDL cholesterol by up to 66% and AZD0780 by 52%, with promising early results but pending outcome trials.